Skip to main content

Altman Peter's Form 4/A amendment

Amended

BioCardia, Inc. (BCDA) · filed Apr 14, 2023

Accession no.
0001437749-23-010355
Filed
Apr 14, 2023
Trade date
May 13, 2022
Filing delay
336 days
Rule 10b5-1 plan
Not checked
Original filed
May 13, 2022

This filing lists 1 non-derivative transaction. It carries over 3 transactions from the original filing that it did not restate. Open-market purchases total $18.6K. It was filed 336 days after the trade.

This amendment restates part of 0001437749-22-012420 (filed May 13, 2022). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Altman PeterCIK 0001647542Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 13, 2022Common StockAGrant or awardDisposed−3,498$1.37F2−$4,792.26348,943Direct

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001437749-22-012420 (filed May 13, 2022).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001437749-22-012420
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 11, 2022Common StockPPurchaseAcquired+1,000$1.30F1+$1,300334,143Direct
May 12, 2022Common StockPPurchaseAcquired+11,302$1.20F2+$13,562.4345,445Direct
May 13, 2022Common StockPPurchaseAcquired+2,698$1.38F3+$3,723.24348,143Direct

Footnotes on the original

The footnotes that the prices of these transactions refer to on the original filing.

F1

This transaction was executed in multiple trades ranging from $1.29 to $1.30 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

F2

This transaction was executed in multiple trades ranging from $1.13 to $1.40 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades ranging from $1.32 to $1.45 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The original Form 4 filed on May 13, 2022 incorrectly reported that 2,698 shares were purchased. 3,498 shares were purchased on May 13, 2022 and are correctly reported herein.

F2

This transaction was executed in multiple trades ranging from $1.32 to $1.45 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

The original Form 4 incorrectly reported that 348,143 shares were beneficially owned following the reported transaction. The corrected amount is reported herein.

Read the full filing on SEC EDGAR (opens in a new tab)